Technology | August 29, 2006

Nuclear Stress Test Combines Assessment of Perfusion, Function

Offering a combination of perfusion and function information in a single nuclear stress test, Lantheus Medical Imaging's Cardiolite kit for the preparation of technetium Tc99m sestamibi for injection enables physicians to assess patient risk and optimize patient management.
Because perfusion is a strong predictor of myocardial infarction and cardiac death, doctors imaging with Cardiolite can evaluate the extent of disease, measure severity of perfusion defects and determine reversibility of defects. Testing myocardial function with Cardiolite means physicians can determine left ventricular ejection fraction and regional left ventricular function as well as wall motion and wall thickening. Cardiolite provides insights for specific patient populations with known or suspected CAD who may present with atypical symptoms.


Related Content

News | Radiopharmaceuticals and Tracers

April 13, 2023 β€” A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin ...

Home April 13, 2023
Home
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 β€” On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Home November 05, 2022
Home
News | Radiopharmaceuticals and Tracers

June 24, 2022 β€” Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive ...

Home June 24, 2022
Home
News | Radiopharmaceuticals and Tracers

August 2, 2019 β€” The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) ...

Home August 02, 2019
Home
News | Radiopharmaceuticals and Tracers

July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot ...

Home July 16, 2019
Home
News | Radiopharmaceuticals and Tracers

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel ...

Home June 05, 2019
Home
News | Radiopharmaceuticals and Tracers

May 17, 2019 β€” Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular ...

Home May 17, 2019
Home
News | Radiopharmaceuticals and Tracers | Jeff Zagoudis, Associate Editor

May 10, 2019 β€” Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in ...

Home May 10, 2019
Home
News | Radiopharmaceuticals and Tracers

October 12, 2018 β€” The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) β€” the voice of the radionuclide ...

Home October 12, 2018
Home
Feature | Radiopharmaceuticals and Tracers | Dave Fornell

February 8, 2018 β€” The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took ...

Home February 26, 2018
Home
Subscribe Now